Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim signs licence agreement

Boehringer Ingelheim signs licence agreement

3rd October 2008

Boehringer Ingelheim (BI) and Japanese company Evec have signed a licence agreement for one of the latter’s fully-human therapeutic antibody programmes.

Details of the agreement involve BI obtaining exclusive global commercialisation and development rights in return for an upfront payment to Evec of up to 55 million euros (43 million pounds).

This figure is dependent on development phases and associated royalty payments.

Dr Andreas Barner is vice-chairman of BI’s board corporate division of pharma research, development and medicine, and said the company was “impressed” by Evec’s generation of fully-human antibodies.

“[We] are delighted to be one of the first western multinational pharmaceutical companies to enter into a license agreement with a Japanese bio venture company,” he added.

“This collaboration has the potential to answer the patients’ and physicians’ need for new treatments that are both safe and efficacious.”

The chairman of Sapporo-based Evec, Professor Kenzo Takada, said the group was “excited” to enter the agreement and it highlighted a development milestone.

Meanwhile, BI recently revealed results of its European Cooperative Acute Stroke Study, which found that using Actilyse (alteplase) as a treatment between three and 4.5 hours following the onset of a stroke can result in improved clinical outcome.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.